#	Article	IF	Citations
1	A Conserved Cysteine Residue in Coxsackievirus B3 Protein 3A with Implication for Elevated Virulence. Viruses, 2022, 14, 769.	3.3	0
2	Exploration of Analgesia with Tramadol in the Coxsackievirus B3 Myocarditis Mouse Model. Viruses, 2021, 13, 1222.	3.3	2
3	Coxsackievirus B3 Infection of Human iPSC Lines and Derived Primary Germ-Layer Cells Regarding Receptor Expression. International Journal of Molecular Sciences, 2021, 22, 1220.	4.1	3
4	MiRâ€375â€mediated suppression of engineered coxsackievirus B3 in pancreatic cells. FEBS Letters, 2020, 594, 763-775.	2.8	9
5	Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. Cardiovascular Research, 2020, 116, 1756-1766.	3.8	16
6	Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps. Journal of Virology, 2020, 94, .	3.4	2
7	Early Treatment of Coxsackievirus B3â€"Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005250.	3.9	14
8	The immunoproteasomeâ€specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis. EMBO Molecular Medicine, 2018, 10, 200-218.	6.9	48
9	Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma. Human Gene Therapy, 2018, 29, 1301-1314.	2.7	19
10	Infection of iPSC Lines with Miscarriage-Associated Coxsackievirus and Measles Virus and Teratogenic Rubella Virus as a Model for Viral Impairment of Early Human Embryogenesis. ACS Infectious Diseases, 2017, 3, 886-897.	3.8	15
11	NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis. Circulation: Heart Failure, 2017, 10, .	3.9	60
12	Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters. Molecular Therapy - Nucleic Acids, 2017, 8, 300-316.	5.1	18
13	Biological antivirals for treatment of adenovirus infections. Antiviral Therapy, 2016, 21, 559-566.	1.0	13
14	The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection. Journal of Virology, 2016, 90, 5601-5610.	3.4	15
15	Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus. Antiviral Research, 2016, 136, 1-8.	4.1	13
16	Combination of RNA Interference and Virus Receptor Trap Exerts Additive Antiviral Activity in Coxsackievirus B3-induced Myocarditis in Mice. Journal of Infectious Diseases, 2015, 211, 613-622.	4.0	17
17	A Novel Artificial MicroRNA Expressing AAV Vector for Phospholamban Silencing in Cardiomyocytes Improves Ca2+ Uptake into the Sarcoplasmic Reticulum. PLoS ONE, 2014, 9, e92188.	2.5	19
18	Proteomic Analysis of the Multimeric Nuclear Egress Complex of Human Cytomegalovirus. Molecular and Cellular Proteomics, 2014, 13, 2132-2146.	3.8	79

#	Article	IF	Citations
19	Virus-Host Coevolution in a Persistently Coxsackievirus B3-Infected Cardiomyocyte Cell Line. Journal of Virology, 2011, 85, 13409-13419.	3.4	45
20	Prevention of Cardiac Dysfunction in Acute Coxsackievirus B3 Cardiomyopathy by Inducible Expression of a Soluble Coxsackievirus-Adenovirus Receptor. Circulation, 2009, 120, 2358-2366.	1.6	67
21	Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3. Antiviral Research, 2009, 83, 298-306.	4.1	24
22	Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. Journal of Molecular Medicine, 2008, 86, 987-997.	3.9	73